“Too many medtech startups fail unnecessarily due to a lack of bridge, or seed funding, required to advance far enough in the commercialization process to attract investment by a larger device company,” said Tiffany Wilson, CEO of Atlanta-based GCMI and its preclinical testing and training arm T3 Labs, in a news release. “The new accelerator and BD’s support provides a new source of critically needed funding and support for local and regional medtech startups, and the ecosystem as a whole, to take a measurable step forward.”
BD is expected to support the first company to complete the GCMI Medtech Accelerator program. Startup companies that are admitted to the accelerator program will be selected by a team from GCMI, an industry partner, investor and other relevant subject matter experts.
Get the full story on our sister site, Medical Design & Outsourcing.
